Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma

被引：181
|
作者：
Braun, David A. [1 ]
Ishii, Yuko [2 ]
Walsh, Alice M. [2 ]
Van Allen, Eliezer M. [1 ]
Wu, Catherine J. [1 ]
Shukla, Sachet A. [1 ]
Choueiri, Toni K. [1 ]
机构：
[1] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
[2] Bristol Myers Squibb, Lawrenceville, NJ USA
来源：
JAMA ONCOLOGY | 2019年 / 5卷 / 11期
关键词：
D O I：
10.1001/jamaoncol.2019.3158
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1631 / 1633
页数：3
相关论文
共 50 条
  • [21] Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression
    Joseph, Richard W.
    Kapur, Payal
    Serie, Daniel J.
    Parasramka, Mansi
    Ho, Thai H.
    Cheville, John C.
    Frenkel, Eugene
    Parker, Alexander S.
    Brugarolas, James
    JOURNAL OF UROLOGY, 2016, 195 (01): : 180 - 187
  • [22] PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma
    Chowdhury, Basudev
    Porter, Elizabeth G.
    Stewart, Jane C.
    Ferreira, Christina R.
    Schipma, Matthew J.
    Dykhuizen, Emily C.
    PLOS ONE, 2016, 11 (04):
  • [23] PBRM1 and KDM5C loss modulate the tumor immune microenvironment of clear cell renal carcinoma
    Valdivia, Carlos
    de Nicolas-Hernandez, Javier
    Lanillos, Javier
    Martinez-Montes, Angel M.
    Arenas, Alicia
    Mellid, Sara
    Monteagudo, Maria
    Torres, Raul
    Jose Caleiras-Pires, Eduardo
    Leandro, Javier
    Robledo, Mercedes
    Rodriguez-Antona, Cristina
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 68 - 69
  • [24] PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review
    Castello Dias Carneiro, Andre Paterno
    Marques Monteiro, Fernando Sabino
    Soares, Andrey
    KIDNEY CANCER, 2021, 5 (02) : 79 - 92
  • [25] Significance of PBRM1 mutation in disease progress and drug selection in clear cell renal cell carcinoma
    He, Donghua
    Ma, Tianyan
    Yi, Ni
    Zhang, Sijie
    Ding, Guanxiong
    BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, 2024, 40 (04) : 3901 - 3915
  • [26] The role of PBRM1 as tumor suppressor gene in renal cell carcinomas
    Jandrig, Burkhard
    Ikromov, Odiljon
    Hoegner, Anica
    Wendler, Johann J.
    Schostak, Martin
    Krause, Hans
    CANCER RESEARCH, 2014, 74 (19)
  • [27] Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?
    V. Demidova, Elena
    Ghatalia, Pooja
    Arora, Sanjeevani
    EUROPEAN UROLOGY, 2022, 81 (02) : 149 - 150
  • [28] Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma
    Chen, Jiayi
    Yao, Chunlin
    Qiao, Nan
    Ge, Yangyang
    Li, Jianhua
    Lin, Yun
    Yao, Shanglong
    CANCER MEDICINE, 2021, 10 (19): : 6590 - 6609
  • [29] In Search of Clinical Biomarkers of Response to Checkpoint Inhibitor Therapy in Renal Cell Carcinoma
    Fan, Alice C.
    Leppert, John T.
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [30] Fucosylated pro-haptoglobin predicts clinical response to immune checkpoint inhibitor in metastatic renal cell carcinoma
    Kato, Taigo
    Morishita, Koichi
    Tomiyama, Eisuke
    Fujita, Kazutoshi
    Ishizuya, Yu
    Yamamoto, Yoshiyuki
    Hatano, Koji
    Kawashima, Atsunari
    Miyoshi, Eiji
    Nonomura, Norio
    CANCER SCIENCE, 2024, 115 : 1404 - 1404
12345